验证MTXPK工具在预测在延迟甲基清除患者中的葡萄糖酶利用:一个回顾性研究
Kathie Wu1, Chandrakala Dadeboyina1, Gwen Hua1
1Hematology/Oncology, Geisinger Medical Center, Danville, USA.
Cureus
|February 19, 2026
概括
MTXPK.org工具准确地预测甲状腺酸盐 (MTX) 清除,识别需要葡萄糖酶的患者. 这种临床决策工具有助于避免不必要的葡萄糖酶的使用,减少潜在的MTX毒性风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 临床信息学 临床信息学
背景情况:
- 葡萄糖酶是一种酶,用于治疗甲醇 (MTX) 毒性.
- 对临床医生来说,确定适当的葡萄糖酶的使用可能是具有挑战性的.
- 高剂量甲索特雷克萨 (HDMTX) 治疗需要仔细监测延迟清除和潜在的毒性.
研究的目的:
- 评估MTXPK.org基于网络的临床决策工具在指导葡萄糖酶的管理中的预测价值.
- 评估MTXPK.org在识别高风险的MTX毒性患者中的准确性,这些患者可能从葡萄糖酶中受益.
- 为了确定MTXPK.org是否可以帮助限制不必要的葡萄糖酶使用.
主要方法:
- 从2000年至2023年收到HDMTX和葡萄糖酶治疗的患者的回顾性数据收集.
- 收集的患者数据包括人口统计,MTX剂量,肌素,血清MTX,专蛋白和多流液状态.
- 将数据输入到MTXPK工具中,以比较个人MTX清除率与预测的人口曲线.
主要成果:
- 100%的MTXPK预测与已建立的葡萄糖酶管理指南保持一致.
- MTXPK.org预测,61.5%的患者应该接受葡萄糖酶.
- 该工具发现38.5%的患者不必要接受葡萄糖酶,这表明改善临床决策的潜力.
结论:
- MTXPK.org工具是临床医生管理延迟MTX清除患者的客观资源.
- 使用MTXPK.org可以帮助合理的葡萄糖酶的管理,防止不必要的治疗.
- 通过MTXPK.org进行客观评估可以帮助减轻与MTX毒性和葡萄糖酶使用相关的意外结果.
相关概念视频
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
16
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
16
Therapeutic Drug Monitoring: Affecting Factors
258
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
258
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
213
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
213
Pharmacogenetics of Drug Metabolism: Overview
23
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
23
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
265
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
265
Noncompartmental Analysis: Mean Transit, Absorption and Dissolution Time
418
When drugs are administered extravascularly, a comprehensive evaluation through noncompartmental analysis becomes imperative. This analytical approach considers various parameters that play a crucial role in understanding the pharmacokinetics of these drugs.
One of the key parameters is the mean transit time (MTT), which refers to the total duration required for drug molecules to transit through the body. MTT is determined by calculating the ratio of the area under the moment curve to the area...
One of the key parameters is the mean transit time (MTT), which refers to the total duration required for drug molecules to transit through the body. MTT is determined by calculating the ratio of the area under the moment curve to the area...
418


